{"id":"colchicine-oral-product","safety":{"commonSideEffects":[{"rate":"10–30","effect":"Diarrhea"},{"rate":"5–15","effect":"Nausea"},{"rate":"5–10","effect":"Abdominal pain"},{"rate":"2–8","effect":"Vomiting"},{"rate":null,"effect":"Myopathy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Colchicine disrupts microtubule dynamics, which impairs the movement and function of neutrophils and other inflammatory cells. This reduces the inflammatory cascade and production of pro-inflammatory cytokines. In cardiovascular disease, this anti-inflammatory effect may reduce atherosclerotic plaque progression and recurrent cardiovascular events.","oneSentence":"Colchicine inhibits microtubule polymerization by binding to tubulin, thereby suppressing inflammatory cell migration and activation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:06:38.270Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome or chronic coronary disease (post-myocardial infarction)"},{"name":"Cardiovascular event reduction in patients with established coronary artery disease"}]},"trialDetails":[{"nctId":"NCT04774159","phase":"PHASE3","title":"Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk","status":"RECRUITING","sponsor":"Population Health Research Institute","startDate":"2021-05-06","conditions":"Peripheral Arterial Disease, Atherosclerosis of Extremities, Inflammation","enrollment":6150},{"nctId":"NCT06212271","phase":"EARLY_PHASE1","title":"Mechanistic Clinical Trial of Colchicine in Patients With Peripheral Artery Disease","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2024-09-25","conditions":"Peripheral Artery Disease","enrollment":24},{"nctId":"NCT07232069","phase":"PHASE3","title":"PRE-EMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis","status":"NOT_YET_RECRUITING","sponsor":"Duke University","startDate":"2026-07-01","conditions":"Coronary Artery Disease Risk Factors Multiple, Coronary Artery Disease Progression, Prevention & Control","enrollment":1500},{"nctId":"NCT07349875","phase":"PHASE4","title":"Colchicine Treatment for Non-Flow-Limiting Coronary Plaque by Coronary CTA: A Randomized Controlled Trial","status":"RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2026-01-01","conditions":"Coronary Artery Disease (CAD)","enrollment":3826},{"nctId":"NCT03128905","phase":"PHASE3","title":"Trial of Colchicine Versus Prednisone for the Treatment of Acute CPPD Arthritis","status":"COMPLETED","sponsor":"Lille Catholic University","startDate":"2018-02-05","conditions":"Chondrocalcinosis","enrollment":111},{"nctId":"NCT06847204","phase":"PHASE1, PHASE2","title":"EFFICACY OF COLCHICINE IN IMPROVING CLINICAL OUTCOMES IN PATIENTS WITH MILD TO MODERATE COVID-19 PNEUMONIA IN LAHORE: A RANDOMIZED CONTROL TRIAL","status":"COMPLETED","sponsor":"Zaeema Kanwal","startDate":"2025-02-24","conditions":"COVID - 19","enrollment":66},{"nctId":"NCT06090890","phase":"PHASE4","title":"Anti-inflammatory Therapy for Recurrent In-stent Restenosis","status":"RECRUITING","sponsor":"Fu Wai Hospital, Beijing, China","startDate":"2023-10-30","conditions":"In-stent Restenosis","enrollment":252},{"nctId":"NCT04879368","phase":"PHASE3","title":"RegoNivo vs Standard of Care Chemotherapy in AGOC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2021-06-01","conditions":"Gastro-Oesophageal Cancer","enrollment":450},{"nctId":"NCT04382443","phase":"PHASE4","title":"Oral Colchicine in Argentina to Prevent Restenosis","status":"COMPLETED","sponsor":"Centro de estudios en Cardiologia Intervencionista","startDate":"2020-03-12","conditions":"Coronary Artery Disease, Restenosis of Coronary Artery Stent, Atherosclerosis","enrollment":410},{"nctId":"NCT05890664","phase":"PHASE3","title":"Colchicine After Electrocardioversion for Atrial Fibrillation","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2024-04-14","conditions":"Atrial Fibrillation, Cardiac Arrhythmia","enrollment":416},{"nctId":"NCT05698680","phase":"PHASE4","title":"Prednisolone Versus Colchicine for Acute Gout in Primary Care","status":"RECRUITING","sponsor":"University Medicine Greifswald","startDate":"2023-01-18","conditions":"Acute Gout","enrollment":314},{"nctId":"NCT06813079","phase":"PHASE2","title":"Using Tumor Models to Determine Treatments","status":"NOT_YET_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2025-02-17","conditions":"Pancreatic Ductal Carcinoma, Advanced Cancer, Epithelial Tumor","enrollment":25},{"nctId":"NCT03913442","phase":"PHASE4","title":"Colchicine for the Treatment of Osteoarthritis of the Knee","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2019-05-15","conditions":"Osteoarthritis, Osteo Arthritis Knee","enrollment":120},{"nctId":"NCT06768294","phase":"PHASE2","title":"Baricitinib in CPPD - the BAPTIST Study","status":"NOT_YET_RECRUITING","sponsor":"I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio","startDate":"2025-01","conditions":"Calcium Pyrophosphate Deposition Disease, Chondrocalcinosis","enrollment":32},{"nctId":"NCT05936281","phase":"PHASE2","title":"A Study of the Efficacy of Genakumab in Prevention of Acute Flares in Gout Patients Initiating Urate-lowering TherapyUrate-lowering (GenSci048-202)","status":"COMPLETED","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2023-07-20","conditions":"Gout, Gout Initiating Urate-loweringUrate-lowering Therapy","enrollment":165},{"nctId":"NCT04181996","phase":"PHASE3","title":"Canadian Study of Arterial Inflammation in Patients With Diabetes and Vascular Events: EvaluatioN of Colchicine","status":"RECRUITING","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2020-08-01","conditions":"Cardiovascular Diseases, Atherosclerosis, Inflammation","enrollment":115},{"nctId":"NCT04381936","phase":"PHASE3","title":"Randomised Evaluation of COVID-19 Therapy","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2020-03-19","conditions":"Severe Acute Respiratory Syndrome","enrollment":70000},{"nctId":"NCT04848857","phase":"PHASE4","title":"Colchicine for the Stability of Coronary Plaque in Acute Coronary Syndrome (COLOCT)","status":"COMPLETED","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2021-05-03","conditions":"Acute Coronary Syndrome","enrollment":128},{"nctId":"NCT06102720","phase":"PHASE4","title":"Efficacy of Colchicine in Preventing Recurrent Stroke in the Patients With Acute Atherothrombotic Ischemic Stroke During Hospitalization","status":"UNKNOWN","sponsor":"Mikhail Zykov","startDate":"2023-01-12","conditions":"Ischemic Stroke","enrollment":200},{"nctId":"NCT06062277","phase":"PHASE2","title":"COlchicine iN Circulating Inflammatory Markers After StrokE (CONCISE)","status":"UNKNOWN","sponsor":"University College Dublin","startDate":"2023-10","conditions":"Ischemic Stroke, Atherosclerosis","enrollment":91},{"nctId":"NCT04756128","phase":"PHASE2","title":"Impact of Colchicine and Low-dose Naltrexone on COVID-19","status":"COMPLETED","sponsor":"HealthPartners Institute","startDate":"2021-01-25","conditions":"Covid19","enrollment":142},{"nctId":"NCT04218786","phase":"PHASE2","title":"Effect of Colchicine in Patients With Myocardial Infarction","status":"WITHDRAWN","sponsor":"Shifa Tameer-e-Millat University","startDate":"2025-12","conditions":"Myocardium; Injury, Myocardial Infarction, Myocardial Ischemia","enrollment":""},{"nctId":"NCT05802992","phase":"PHASE3","title":"The Efficacy and Safety of Colchicine Combined With Conventional Therapy in Multiple Myeloma Patients","status":"UNKNOWN","sponsor":"Affiliated Hospital of Nantong University","startDate":"2022-03-30","conditions":"Multiple Myeloma","enrollment":30},{"nctId":"NCT05324423","phase":"PHASE1","title":"To Evaluate Drug Interactions Between XNW3009, Febuxostat, and Colchicine in Patients With Gout","status":"UNKNOWN","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2021-10-18","conditions":"Gout","enrollment":20},{"nctId":"NCT02366091","phase":"PHASE2","title":"Inflammation and Coronary Endothelial Function","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2015-01","conditions":"Coronary Artery Disease","enrollment":111},{"nctId":"NCT04997551","phase":"PHASE3","title":"Double Blind Randomized Clinical Trial of Use of Colchicine Added to Standard Treatment in Hospitalized With Covid-19","status":"UNKNOWN","sponsor":"Biogipuzkoa Health Research Institute","startDate":"2020-09-08","conditions":"COVID-19 Infection","enrollment":752},{"nctId":"NCT02926248","phase":"PHASE4","title":"Effect of Colchicine on Range of Motion After Manipulation Under Anesthesia for the Stiff Total Knee Replacement","status":"SUSPENDED","sponsor":"Hospital for Special Surgery, New York","startDate":"2016-05","conditions":"Manipulation Under Anesthesia","enrollment":112},{"nctId":"NCT03131583","phase":"PHASE1","title":"The Drug-Drug Interaction of SHR4640, Febuxostat and Colchicine in Patients With Gout","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2017-02-17","conditions":"Gout","enrollment":15},{"nctId":"NCT01112982","phase":"PHASE4","title":"An Assessment of Chronic Synovial-Based Inflammation and Its Role With Serum Urate Levels.","status":"COMPLETED","sponsor":"University of South Florida","startDate":"2010-05","conditions":"Gout","enrollment":74},{"nctId":"NCT02139046","phase":"PHASE3","title":"Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-04","conditions":"Gout","enrollment":1790},{"nctId":"NCT02128490","phase":"PHASE2","title":"Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout and Moderate Renal Impairment","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-05","conditions":"Gout, Moderate Renal Impairment","enrollment":189},{"nctId":"NCT02252835","phase":"PHASE2","title":"Evaluate the PK, PD, and Safety of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Patients With Gout","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-08","conditions":"Gout, Hyperuricemia","enrollment":32},{"nctId":"NCT02060552","phase":"PHASE4","title":"Immune Molecular and Inflammatory Cytokines Dysfunction Analysis in Gout Patients With Different Urate Levels","status":"COMPLETED","sponsor":"Tongji Hospital","startDate":"2013-01","conditions":"Primary Gout","enrollment":96},{"nctId":"NCT01601132","phase":"PHASE4","title":"Drug Interaction Study of Colchicine and Theophylline","status":"COMPLETED","sponsor":"Takeda","startDate":"2012-05","conditions":"Healthy","enrollment":30},{"nctId":"NCT01040845","phase":"PHASE1","title":"A Pharmacokinetic Study of Colchicine With an Oral Contraceptive","status":"COMPLETED","sponsor":"Mutual Pharmaceutical Company, Inc.","startDate":"2007-08","conditions":"Pharmacokinetics","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Colchicine Oral Product","genericName":"Colchicine Oral Product","companyName":"Ottawa Heart Institute Research Corporation","companyId":"ottawa-heart-institute-research-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Colchicine inhibits microtubule polymerization by binding to tubulin, thereby suppressing inflammatory cell migration and activation. Used for Acute coronary syndrome or chronic coronary disease (post-myocardial infarction), Cardiovascular event reduction in patients with established coronary artery disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}